...数、骨髓增生情况、治疗方案等对缓解率的影响;采用Kaplan-Meier曲线分析不同的治疗方案的应用对总生存期（Overall Survival OS）和无病生存期（Disease-free Survival DFS）的影响;同时分别对ATRA及ATRA+As2O3组进一步按初诊时白细胞水平高低分为高危组和低危...
基于24个网页-相关网页
PFS, rather than overall survival (OS), was accepted by regulatory authorities in the United States and Europe as the endpoint for approval of bevacizumab for the renal cell carcinoma indication.
欧美权威机构接受PFS作为观察终点，而非总生存期（OS），肾细胞癌作为贝伐单抗的适应症范围。
Secondary end points included overall survival (OS) and overall response rate (ORR) per IRC.
次要终点包括IRC评估的总生存期(OS)和总缓解率(ORR)。
The primary end point was amended from overall survival (OS) to progression-free survival (PFS).
首要观察终点从总生存期(OS)改为无进展生存期(PFS)。
应用推荐